Bases Neurobiológicas y Psicológicas de los Trastornos Mentales. Trastornos del Neurodesarrollo

Lefaucheur, JP; Colzi, C; Hollander, E; Pampaloni, I; Van Ameringen, M; Baeken, C; Fusar-Poli, P; Arango, C; Fontenelle, LF; Batail, JM; Brunoni, AR; Nicolini, H; Haffen, E; Soriano-Mas, C; Rodriguez, CI; Dell'Osso, BM; Vieta, E; Sauvaget, A; Szekely, D; Mayer-Linderberg, A; Denys, D; Stein, DJ; Drapier, D; Voon, V; Pallanti, S.

Comparison between accelerated and standard or sham rTMS in the treatment of depression: A systematic review

NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS. 2025; 173: Nº de citas: 17 [doi:10.1016/j.neubiorev.2025.106140]

Bajracharya P; Ballem R; Chen J; Andrés-Camazón P; Khasayeva N; Calhoun V; Liu J; Iraji A.

LINKING MULTI-SCALE BRAIN CONNECTIVITY WITH VIGILANCE, WORKING MEMORY, AND BEHAVIOR IN ADOLESCENTS.

Biorxiv : The Preprint Server For Biology. 2025; : [doi:10.1101/2025.05.09.653144]

Alayo, I; Pujol, O; Alonso, J; Ferrer, M; Amigo, F; Diest, APV; Aragonès, E; Peña, AA; Del Barco, AA; Campos, M; Espuga, M; González-Pinto, A; Haro, JM; López-Fresneña, N; de Salázar, ADM; Molina, JD; Ortí-Lucas, RM; Parellada, M; Pelayo-Terán, JM; Forjaz, MJ; Pérez-Zapata, A; Pijoan, JI; Plana, N; Polentinos-Castro, E; Puig, MT; Rius, C; Sanz, F; Serra, C; Urreta-Barallobre, I; Bruffaerts, R; Vieta, E; Pérez-Solá, V; Mortier, P; Vilagut, G.

Identifying most important predictors for suicidal thoughts and behaviours among healthcare workers active during the Spain COVID-19 pandemic: a machine-learning approach

Epidemiology and Psychiatric Sciences. 2025; 34: Nº de citas: 2 [doi:10.1017/S2045796025000198]

Segura, AG; Prohens, L; Julià, L; Amoretti, S; Ribero, M; Pino-Camacho, L; Cano-Escalera, G; Mane, A; Rodriguez-Jimenez, R; Roldan, A; Sarró, S; Ibañez, A; Usall, J; Lobo, A; Garcia-Rizo, C; Cuesta, MJ; Parellada, M; González-Pinto, A; Berrocoso, E; Mas, S; Rodriguez, N; Perez-Ramos, A; Salmeron, S; González-Peñas, J; Gurriarán, X; Farré, A; Pousa, E; Zorrilla, I; Mar-Barrutia, L; Trabsa, A; Martinez, L; Sánchez-Cabezudo, A; Jiménez-López, E; Pomarol-Clotet, E; Salvador, R; Butjosa, A; Elena, RA; Moreno-Izco, L; Torres, AMS; Saiz, J; León-Quismondo, L; Rivero, O; González-Blanco, L; De-la-Camára, C; Bernardo, M.

Methylation profile scores of environmental exposures and risk of relapse after a first episode of schizophrenia

EUROPEAN NEUROPSYCHOPHARMACOLOGY. 2025; 94: 4-15 Nº de citas: 3 [doi:10.1016/j.euroneuro.2025.02.003]

Szerman N; Vega P; Roncero C; Peris L; Grau-López L; Basurte-Villamor I.

Cariprazine as a maintenance treatment in dual schizophrenia: a 6-month observational study in patients with schizophrenia and cannabis use disorder.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY. 2025; 40(3): 167-175 Nº de citas: 9 [doi:10.1097/YIC.0000000000000568]

Varo, C; Barrigón, ML; Rider, J; Reguera, P; Mayo-Jaraquemada, A; Canal-Rivero, M; Garrido-Torres, N; Baca-Garcia, E; Ruiz-Veguilla, M; Crespo-Facorro, B.

Characteristics of Self-Harm in an Emergency Situation Among Youth: A Longitudinal Five- Year Cohort Study

Research on Child and Adolescent Psychopathology. 2025; 53: 1185-1198 Nº de citas: 1 [doi:10.1007/s10802-025-01309-x]

Janssen, J; Gallego, AG; Díaz-Caneja, CM; Lois, NG; Janssen, N; González-Peñas, J; Gordaliza, PM; Buimer, E; van Haren, N; Arango, C; Kahn, R; Pol, HEH; Schnack, HG.

Heterogeneity of morphometric similarity networks in health and schizophrenia

Schizophrenia. 2025; 11(1): Nº de citas: 10 [doi:10.1038/s41537-025-00612-2]

Lopez-Morinigo, JD; Fiorillo, A; Dom, G; Arango, C.

Mental health status of the European population and its determinants: A cross-national comparison study

EUROPEAN PSYCHIATRY. 2025; 68(1): Nº de citas: 4 [doi:10.1192/j.eurpsy.2025.2449]

Gorwood, P; Yildirim, M; Madera-McDonough, J; Fagiolini, A; Arango, C; Correll, CU; Arcà, E; Barlassina, A; Selveindran, S; Sahota, N; Kane, JM.

Assessment of functional recovery in patients with schizophrenia, with a focus on early-phase disease: results from a Delphi consensus and narrative review

BMC Psychiatry. 2025; 25(1): Nº de citas: 11 [doi:10.1186/s12888-025-06725-3]

Freeman, K; Zwicker, A; Fullerton, JM; Hafeman, DM; van Haren, NEM; Merranko, J; Goldstein, BI; Stapp, EK; de la Serna, E; Moreno, D; Sugranyes, G; Mas, S; Roberts, G; Toma, C; Schofield, PR; Edenberg, HJ; Wilcox, HC; McInnis, MG; Propper, L; Pavlova, B; Stewart, SA; Denovan-Wright, EM; Rouleau, GA; Castro-Fornieles, J; Hillegers, MHJ; Birmaher, B; Mitchell, PB; Alda, M; Nurnberger, JI; Uher, R.

Polygenic Scores and Mood Disorder Onsets in the Context of Family History and Early Psychopathology

JAMA Network Open. 2025; 8(4): Nº de citas: 4 [doi:10.1001/jamanetworkopen.2025.5331]

de la Serna, E; Moreno, D; Sugranyes, G; Camprodon-Boadas, P; Ilzarbe, D; Bigorra, A; Mora-Maltas, B; Baeza, I; Flamarique, I; Parrilla, S; Díaz-Caneja, CM; Moreno, C; Borras, R; Torrent, C; Garcia-Rizo, C; Castro-Fornieles, J.

Effects of parental characteristics on the risk of psychopathology in offspring: a 4-year follow-up study

EUROPEAN CHILD & ADOLESCENT PSYCHIATRY. 2025; 34: 3035-3045 [doi:10.1007/s00787-025-02719-4]

Arango, C; Fiorillo, A; Dom, G; Lopez-Morinigo, JD.

Responsiveness of European countries to the population mental health needs: A cross-national comparison study

EUROPEAN PSYCHIATRY. 2025; 68(1): Nº de citas: 4 [doi:10.1192/j.eurpsy.2025.2448]

Díaz-Cutraro, L; Verdaguer-Rodríguez, M; García-Mieres, H; Ferrer-Quintero, M; López-Carrilero, R; Palma-Sevillano, C; Lamarca, M; Espinosa, V; Barrigón, ML; González-Higueras, F; Pousa, E; Grasa, E; Lorente-Rovira, E; Gutiérrez-Zotes, A; Barajas, A; Ruiz-Delgado, I; Cid, J; Moritz, S; Rico, J; Sevilla-Llewellyn-Jones, J; Haro, JM; Ochoa, S.

Sex-based differences in Jumping to Conclusions: a multidimensional analysis of first-episode psychosis

Schizophrenia. 2025; 11(1): Nº de citas: 5 [doi:10.1038/s41537-025-00579-0]

Bugarski-Kirola, D; Liu, IY; Arango, C; Marder, SR.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Pimavanserin as an Adjunctive Treatment for the Negative Symptoms of Schizophrenia (ADVANCE-2) in Patients With Predominant Negative Symptoms

SCHIZOPHRENIA BULLETIN. 2025; 52: Nº de citas: 5 [doi:10.1093/schbul/sbaf034]

Addington, J; Liu, L; Braun, A; Auther, A; Calkins, ME; Cornblatt, BA; Corcoran, CM; Fusar-Poli, P; Kerr, MJ; Mourgues-Codern, CV; Nunez, AR; Oliver, D; Strauss, GP; Walsh, BC; Alameda, LK; Arango, C; Breitborde, NJK; Broome, MR; Cadenhead, KS; Carrion, RE; Chen, EYH; Choi, J; Coleman, MJ; Conus, P; Diaz-Caneja, CM; Dwyer, D; Ellman, LM; Faghankhani, M; Gaspar, PA; Gerber, C; Glenthoj, LB; Horton, LE; Hui, C; Jacobs, GR; Kambeitz, J; Kambeitz-Ilankovic, L; Keshavan, MS; Kim, SW; Koutsouleris, N; Kwon, JS; Langbein, K; Lewandowski, KE; Mamah, D; Marcy, PJ; Mathalon, DH; Mittal, VA; Nordentoft, M; Pearlson, GD; Penzel, N; Perez, J; Perkins, DO; Powers, AR III; Rogers, J; Sabb, FW; Schiffman, J; Shah, JL; Silverstein, SM; Smesny, S; Stone, WS; Thompson, A; Thompson, JL; Upthegrove, R; Verma, S; Wang, JJ; Wastler, HM; Wickham, A; Winter-van Rossum, I; Wolf, DH; Bouix, S; Pasternak, O; Kahn, RS; Bearden, CE; Kane, JM; McGorry, PD; Buccilli, K; Nelson, B; Shenton, ME; Woods, SW; Yung, AR.

Sample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia. 2025; 11(1): Nº de citas: 11 [doi:10.1038/s41537-025-00556-7]

Penzel, N; Polosecki, P; Addington, J; Arango, C; Asgari-Targhi, A; Billah, T; Bouix, S; Calkins, ME; Campbell, DE; Cannon, TD; Castro, E; Cho, KIK; Coleman, MJ; Corcoran, CM; Dwyer, D; Frangou, S; Fusar-Poli, P; Glynn, RJ; Haidar, A; Harms, MP; Jacobs, GR; Kambeitz, J; Kapur, T; Kelly, SM; Koutsouleris, N; Abhinandan, KR; Kucukemiroglu, S; Kwon, JS; Lewandowski, KE; Li, QS; Mantua, V; Mathalon, DH; Mittal, VA; Nicholas, S; Pandina, GJ; Perkins, DO; Potter, A; Reichenberg, A; Reinen, J; Sand, MS; Seitz-Holland, J; Shah, JL; Srinivasan, V; Srivastava, A; Stone, WS; Torous, J; Vangel, MG; Wang, JJ; Wolff, P; Yao, BE; Anticevic, A; Wolf, DH; Zhu, H; Bearden, CE; McGorry, PD; Nelson, B; Kane, JM; Woods, SW; Kahn, RS; Shenton, ME; Cecchi, G; Pasternak, O.

Data analysis strategies for the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia. 2025; 11(1): Nº de citas: 3 [doi:10.1038/s41537-025-00561-w]

Kieseppä, V; Lang, U; Healy, C; O'Hare, K; Díaz-Caneja, CM; Gülöksüz, S; Rutten, BPF; Cannon, M; Halt, AH; Riipinen, P; Kelleher, I.

Do psychotic symptoms predict future psychotic disorders in adolescent psychiatry inpatients? A 17-year cohort study

PSYCHOLOGICAL MEDICINE. 2025; 55: Nº de citas: 3 [doi:10.1017/S003329172500073X]

Harms, MP; Cho, KIK; Anticevic, A; Bolo, NR; Bouix, S; Campbell, D; Cannon, TD; Cecchi, G; Goncalves, M; Haidar, A; Hughes, DE; Izyurov, I; John, O; Kapur, T; Kim, N; Kotler, E; Kubicki, M; Kuperman, JM; Laulette, K; Lindberg, U; Markiewicz, C; Ning, LP; Poldrack, RA; Rathi, Y; Romo, PA; Tamayo, Z; Wannan, C; Wickham, A; Yassin, W; Zhou, JH; Addington, J; Alameda, L; Arango, C; Breitborde, NJK; Broome, MR; Cadenhead, KS; Calkins, ME; Chen, EYH; Choi, J; Conus, P; Corcoran, CM; Cornblatt, BA; Diaz-Caneja, CM; Ellman, LM; Fusar-Poli, P; Gaspar, PA; Gerber, C; Glenthoj, LB; Horton, LE; Hui, CLM; Kambeitz, J; Kambeitz-Ilankovic, L; Keshavan, MS; Kim, SW; Koutsouleris, N; Kwon, JS; Langbein, K; Mamah, D; Mathalon, DH; Mittal, VA; Nordentoft, M; Pearlson, GD; Perez, J; Perkins, DO; Powers, AR; Rogers, J; Sabb, FW; Schiffman, J; Shah, JL; Silverstein, SM; Smesny, S; Stone, WS; Strauss, GP; Thompson, JL; Upthegrove, R; Verma, SK; Wang, JJ; Wolf, DH; Kahn, RS; Kane, JM; McGorry, PD; Nelson, B; Woods, SW; Shenton, ME; Wood, SJ; Bearden, CE; Pasternak, O.

The MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program

Schizophrenia. 2025; 11(1): Nº de citas: 7 [doi:10.1038/s41537-025-00581-6]